Stock Detail
DELCATH SYSTEMS INC
Diversified Services
DCTH @ Yahoo Finance | DCTH Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $3.00 | $3.16 | $-0.12 | -3.85% | 0.00 | $3.12 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $3.11 | $2.95 | 571,863 | 143.98M | 551,524 | -4.17 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 3.25 | 3.13 | 3.04 | 2.92 | 2.83 |
Stock Profile
Delcath Systems, Inc., a development stage company, engages in the development and marketing of a medical device for the treatment of liver cancer. It has developed Delcath system, which isolates the liver from the general circulatory system, and administers chemotherapy and other therapeutic agents directly to the liver. The company is in the process of conducting Phase III clinical trials designed to secure marketing approval in the United States and internationally. The Delcath system kit includes disposable components, such as infusion catheter, a thin walled arterial infusion catheter used to deliver chemotherapy to the liver; double balloon catheter, a multipassageway catheter used to isolate and divert the drug-laden blood exiting the liver; extracorporeal filtration circuit, a blood tubing circuit to push the isolated blood through the system's filters and guide the cleansed blood back to the patient; activated carbon blood filters used to remove the chemotherapy agent from the isolated blood; and return catheter, a thin walled blood sheath used to deliver the filtered blood. The company was founded in 1998 and is headquartered in Stamford, Connecticut.